GB414495A
(en)
|
1932-06-13 |
1934-08-09 |
Louis Fillipp Gerdetz |
Improvements in flexible cutter chain
|
ZA737247B
(en)
|
1972-09-29 |
1975-04-30 |
Ayerst Mckenna & Harrison |
Rapamycin and process of preparation
|
US4433059A
(en)
|
1981-09-08 |
1984-02-21 |
Ortho Diagnostic Systems Inc. |
Double antibody conjugate
|
US4444878A
(en)
|
1981-12-21 |
1984-04-24 |
Boston Biomedical Research Institute, Inc. |
Bispecific antibody determinants
|
GB2116183B
(en)
|
1982-03-03 |
1985-06-05 |
Genentech Inc |
Human antithrombin iii dna sequences therefore expression vehicles and cloning vectors containing such sequences and cell cultures transformed thereby a process for expressing human antithrombin iii and pharmaceutical compositions comprising it
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
US4882282A
(en)
|
1985-08-16 |
1989-11-21 |
Immunex Corporation |
DNA sequences encoding bovine interleukin-2
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
US6548640B1
(en)
|
1986-03-27 |
2003-04-15 |
Btg International Limited |
Altered antibodies
|
GB8607679D0
(en)
|
1986-03-27 |
1986-04-30 |
Winter G P |
Recombinant dna product
|
US5869620A
(en)
|
1986-09-02 |
1999-02-09 |
Enzon, Inc. |
Multivalent antigen-binding proteins
|
US5906936A
(en)
|
1988-05-04 |
1999-05-25 |
Yeda Research And Development Co. Ltd. |
Endowing lymphocytes with antibody specificity
|
JPH021556A
(ja)
|
1988-06-09 |
1990-01-05 |
Snow Brand Milk Prod Co Ltd |
ハイブリッド抗体及びその作製方法
|
JP3771253B2
(ja)
|
1988-09-02 |
2006-04-26 |
ダイアックス コープ. |
新規な結合タンパク質の生成と選択
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
US6303121B1
(en)
|
1992-07-30 |
2001-10-16 |
Advanced Research And Technology |
Method of using human receptor protein 4-1BB
|
US6534055B1
(en)
|
1988-11-23 |
2003-03-18 |
Genetics Institute, Inc. |
Methods for selectively stimulating proliferation of T cells
|
US5858358A
(en)
|
1992-04-07 |
1999-01-12 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for selectively stimulating proliferation of T cells
|
US6905680B2
(en)
|
1988-11-23 |
2005-06-14 |
Genetics Institute, Inc. |
Methods of treating HIV infected subjects
|
US6352694B1
(en)
|
1994-06-03 |
2002-03-05 |
Genetics Institute, Inc. |
Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
US5703055A
(en)
|
1989-03-21 |
1997-12-30 |
Wisconsin Alumni Research Foundation |
Generation of antibodies through lipid mediated DNA delivery
|
US5399346A
(en)
|
1989-06-14 |
1995-03-21 |
The United States Of America As Represented By The Department Of Health And Human Services |
Gene therapy
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
US5585362A
(en)
|
1989-08-22 |
1996-12-17 |
The Regents Of The University Of Michigan |
Adenovirus vectors for gene therapy
|
AU6290090A
(en)
|
1989-08-29 |
1991-04-08 |
University Of Southampton |
Bi-or trispecific (fab)3 or (fab)4 conjugates
|
GB8928874D0
(en)
|
1989-12-21 |
1990-02-28 |
Celltech Ltd |
Humanised antibodies
|
US5273743A
(en)
|
1990-03-09 |
1993-12-28 |
Hybritech Incorporated |
Trifunctional antibody-like compounds as a combined diagnostic and therapeutic agent
|
US5427908A
(en)
|
1990-05-01 |
1995-06-27 |
Affymax Technologies N.V. |
Recombinant library screening methods
|
GB9012995D0
(en)
|
1990-06-11 |
1990-08-01 |
Celltech Ltd |
Multivalent antigen-binding proteins
|
ES2139598T3
(es)
|
1990-07-10 |
2000-02-16 |
Medical Res Council |
Procedimientos para la produccion de miembros de parejas de union especifica.
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
DK0564531T3
(da)
|
1990-12-03 |
1998-09-28 |
Genentech Inc |
Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber
|
US5582996A
(en)
|
1990-12-04 |
1996-12-10 |
The Wistar Institute Of Anatomy & Biology |
Bifunctional antibodies and method of preparing same
|
WO1992010591A1
(en)
|
1990-12-14 |
1992-06-25 |
Cell Genesys, Inc. |
Chimeric chains for receptor-associated signal transduction pathways
|
US6319494B1
(en)
|
1990-12-14 |
2001-11-20 |
Cell Genesys, Inc. |
Chimeric chains for receptor-associated signal transduction pathways
|
EP1820858B1
(en)
|
1991-03-01 |
2009-08-12 |
Dyax Corporation |
Chimeric protein comprising micro-protein having two or more disulfide bonds and embodiments thereof
|
US6004811A
(en)
|
1991-03-07 |
1999-12-21 |
The Massachussetts General Hospital |
Redirection of cellular immunity by protein tyrosine kinase chimeras
|
US7049136B2
(en)
|
1991-03-07 |
2006-05-23 |
The General Hospital Corporation |
Redirection of cellular immunity by receptor chimeras
|
NZ241855A
(en)
|
1991-03-07 |
1994-04-27 |
Gen Hospital Corp |
Use of therapeutic cells to obtain cellular response to infection, tumours or autoimmune-generated cells, cells with chimaeric receptors (with binding component and destruction signal), dna encoding the receptor, vectors and antibodies to receptor
|
CA2108147C
(en)
|
1991-04-10 |
2009-01-06 |
Angray Kang |
Heterodimeric receptor libraries using phagemids
|
DE69233482T2
(de)
|
1991-05-17 |
2006-01-12 |
Merck & Co., Inc. |
Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
|
DE4118120A1
(de)
|
1991-06-03 |
1992-12-10 |
Behringwerke Ag |
Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
|
US5199942A
(en)
|
1991-06-07 |
1993-04-06 |
Immunex Corporation |
Method for improving autologous transplantation
|
US6511663B1
(en)
|
1991-06-11 |
2003-01-28 |
Celltech R&D Limited |
Tri- and tetra-valent monospecific antigen-binding proteins
|
DE69233254T2
(de)
|
1991-06-14 |
2004-09-16 |
Genentech, Inc., South San Francisco |
Humanisierter Heregulin Antikörper
|
US5637481A
(en)
|
1993-02-01 |
1997-06-10 |
Bristol-Myers Squibb Company |
Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
|
DE4122599C2
(de)
|
1991-07-08 |
1993-11-11 |
Deutsches Krebsforsch |
Phagemid zum Screenen von Antikörpern
|
ES2136092T3
(es)
|
1991-09-23 |
1999-11-16 |
Medical Res Council |
Procedimientos para la produccion de anticuerpos humanizados.
|
US5932448A
(en)
|
1991-11-29 |
1999-08-03 |
Protein Design Labs., Inc. |
Bispecific antibody heterodimers
|
GB9125768D0
(en)
|
1991-12-04 |
1992-02-05 |
Hale Geoffrey |
Therapeutic method
|
JP4157160B2
(ja)
|
1991-12-13 |
2008-09-24 |
ゾーマ テクノロジー リミテッド |
改変抗体可変領域の調製のための方法
|
ATE151113T1
(de)
|
1992-01-23 |
1997-04-15 |
Merck Patent Gmbh |
Fusionsproteine von monomeren und dimeren von antikörperfragmenten
|
DE69333807T2
(de)
|
1992-02-06 |
2006-02-02 |
Chiron Corp., Emeryville |
Marker für krebs und biosynthetisches bindeprotein dafür
|
GB9203459D0
(en)
|
1992-02-19 |
1992-04-08 |
Scotgen Ltd |
Antibodies with germ-line variable regions
|
US8211422B2
(en)
|
1992-03-18 |
2012-07-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chimeric receptor genes and cells transformed therewith
|
IL104570A0
(en)
|
1992-03-18 |
1993-05-13 |
Yeda Res & Dev |
Chimeric genes and cells transformed therewith
|
AU675223B2
(en)
|
1992-05-08 |
1997-01-30 |
Creative Biomolecules, Inc. |
Chimeric multivalent protein analogues and methods of use thereof
|
ATE452207T1
(de)
|
1992-08-21 |
2010-01-15 |
Univ Bruxelles |
Immunoglobuline ohne leichte ketten
|
US6005079A
(en)
|
1992-08-21 |
1999-12-21 |
Vrije Universiteit Brussels |
Immunoglobulins devoid of light chains
|
US5350674A
(en)
|
1992-09-04 |
1994-09-27 |
Becton, Dickinson And Company |
Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
|
US5639641A
(en)
|
1992-09-09 |
1997-06-17 |
Immunogen Inc. |
Resurfacing of rodent antibodies
|
DE69334287D1
(de)
|
1992-09-25 |
2009-07-09 |
Avipep Pty Ltd |
Zielmoleküle-bindende Polypeptide bestehend aus einer IG-artigen VL Domäne die an eine IG-artige VH Domäne gebunden ist
|
GB9221220D0
(en)
|
1992-10-09 |
1992-11-25 |
Sandoz Ag |
Organic componds
|
GB9221657D0
(en)
|
1992-10-15 |
1992-11-25 |
Scotgen Ltd |
Recombinant bispecific antibodies
|
WO1994009817A1
(en)
|
1992-11-04 |
1994-05-11 |
City Of Hope |
Novel antibody construct
|
GB9323648D0
(en)
|
1992-11-23 |
1994-01-05 |
Zeneca Ltd |
Proteins
|
JP3720353B2
(ja)
|
1992-12-04 |
2005-11-24 |
メディカル リサーチ カウンシル |
多価および多重特異性の結合タンパク質、それらの製造および使用
|
US7211259B1
(en)
|
1993-05-07 |
2007-05-01 |
Immunex Corporation |
4-1BB polypeptides and DNA encoding 4-1BB polypeptides
|
US6476198B1
(en)
|
1993-07-13 |
2002-11-05 |
The Scripps Research Institute |
Multispecific and multivalent antigen-binding polypeptide molecules
|
US5635602A
(en)
|
1993-08-13 |
1997-06-03 |
The Regents Of The University Of California |
Design and synthesis of bispecific DNA-antibody conjugates
|
KR100244960B1
(ko)
|
1993-09-16 |
2000-02-15 |
왈터 엘 쿤, 주니어 |
인간 수용체 h4-1bb
|
WO1995009917A1
(en)
|
1993-10-07 |
1995-04-13 |
The Regents Of The University Of California |
Genetically engineered bispecific tetravalent antibodies
|
WO1995014023A1
(en)
|
1993-11-19 |
1995-05-26 |
Abbott Laboratories |
Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
|
SK78196A3
(en)
|
1993-12-17 |
1997-02-05 |
Sandoz Ag |
Rapamycin demethoxy-derivatives, preparation method thereof and pharmaceutical agent containing them
|
US5362718A
(en)
|
1994-04-18 |
1994-11-08 |
American Home Products Corporation |
Rapamycin hydroxyesters
|
NZ285395A
(en)
|
1994-05-02 |
1998-10-28 |
Novartis Ag |
Chimeric antibody, cancer treatment
|
US7175843B2
(en)
|
1994-06-03 |
2007-02-13 |
Genetics Institute, Llc |
Methods for selectively stimulating proliferation of T cells
|
US5786464C1
(en)
|
1994-09-19 |
2012-04-24 |
Gen Hospital Corp |
Overexpression of mammalian and viral proteins
|
US6294353B1
(en)
|
1994-10-20 |
2001-09-25 |
Morphosys Ag |
Targeted hetero-association of recombinant proteins to multi-functional complexes
|
US5712149A
(en)
|
1995-02-03 |
1998-01-27 |
Cell Genesys, Inc. |
Chimeric receptor molecules for delivery of co-stimulatory signals
|
US6103521A
(en)
|
1995-02-06 |
2000-08-15 |
Cell Genesys, Inc. |
Multispecific chimeric receptors
|
JP4170390B2
(ja)
|
1995-02-24 |
2008-10-22 |
ザ ジェネラル ホスピタル コーポレーション |
受容体キメラによる細胞性免疫の再指示
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
US7067318B2
(en)
|
1995-06-07 |
2006-06-27 |
The Regents Of The University Of Michigan |
Methods for transfecting T cells
|
US6692964B1
(en)
|
1995-05-04 |
2004-02-17 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for transfecting T cells
|
DE69633175T2
(de)
|
1995-05-23 |
2005-08-11 |
Morphosys Ag |
Multimere proteine
|
CA2219659C
(en)
|
1995-06-09 |
2008-03-18 |
Novartis Ag |
Rapamycin derivatives
|
BE1009856A5
(fr)
|
1995-07-14 |
1997-10-07 |
Sandoz Sa |
Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
|
US5989830A
(en)
|
1995-10-16 |
1999-11-23 |
Unilever Patent Holdings Bv |
Bifunctional or bivalent antibody fragment analogue
|
GB9526131D0
(en)
|
1995-12-21 |
1996-02-21 |
Celltech Therapeutics Ltd |
Recombinant chimeric receptors
|
DE69739853D1
(de)
|
1996-02-28 |
2010-06-02 |
Ariad Pharma Inc |
Synthetische rapamycinderivate als multimerisierende wirkstoffe für chimere proteine mit von immunophilin abgeleiteten domänen
|
US5874240A
(en)
|
1996-03-15 |
1999-02-23 |
Human Genome Sciences, Inc. |
Human 4-1BB receptor splicing variant
|
EP0894135B1
(en)
|
1996-04-04 |
2004-08-11 |
Unilever Plc |
Multivalent and multispecific antigen-binding protein
|
EP0937082A2
(en)
|
1996-07-12 |
1999-08-25 |
Ariad Pharmaceuticals, Inc. |
Materials and method for treating or preventing pathogenic fungal infection
|
CA2263129C
(en)
|
1996-08-16 |
2007-01-09 |
Schering Corporation |
Mammalian cell surface antigens; related reagents
|
US6111090A
(en)
|
1996-08-16 |
2000-08-29 |
Schering Corporation |
Mammalian cell surface antigens; related reagents
|
US6114148C1
(en)
|
1996-09-20 |
2012-05-01 |
Gen Hospital Corp |
High level expression of proteins
|
WO1998018809A1
(en)
|
1996-10-25 |
1998-05-07 |
Cell Genesys, Inc. |
Targeted cytolysis of cancer cells
|
ATE332368T1
(de)
|
1997-01-21 |
2006-07-15 |
Gen Hospital Corp |
Selektion von proteinen mittels rns-protein fusionen
|
EP0981548A4
(en)
|
1997-04-30 |
2005-11-23 |
Enzon Inc |
SINGLE CHAIN PROTEINS FIXING ANTIGENS CAPABLE OF GLYCOSYLATION, PRODUCTION AND USES THEREOF
|
US20020062010A1
(en)
|
1997-05-02 |
2002-05-23 |
Genentech, Inc. |
Method for making multispecific antibodies having heteromultimeric and common components
|
US20030207346A1
(en)
|
1997-05-02 |
2003-11-06 |
William R. Arathoon |
Method for making multispecific antibodies having heteromultimeric and common components
|
ATE282092T1
(de)
|
1997-06-11 |
2004-11-15 |
Borean Pharma As |
Trimerisierendes modul
|
CA2293632C
(en)
|
1997-06-12 |
2011-11-29 |
Research Corporation Technologies, Inc. |
Artificial antibody polypeptides
|
US20030060444A1
(en)
|
1997-06-25 |
2003-03-27 |
Celltech Therapeutics, Ltd. |
Cell activation process and reagents therefor
|
GB9713473D0
(en)
|
1997-06-25 |
1997-09-03 |
Celltech Therapeutics Ltd |
Biological products
|
US6015815A
(en)
|
1997-09-26 |
2000-01-18 |
Abbott Laboratories |
Tetrazole-containing rapamycin analogs with shortened half-lives
|
TW557297B
(en)
|
1997-09-26 |
2003-10-11 |
Abbott Lab |
Rapamycin analogs having immunomodulatory activity, and pharmaceutical compositions containing same
|
US6509173B1
(en)
|
1997-10-21 |
2003-01-21 |
Human Genome Sciences, Inc. |
Human tumor necrosis factor receptor-like proteins TR11, TR11SV1, and TR11SV2
|
AU2152299A
(en)
|
1997-10-27 |
1999-05-24 |
Unilever Plc |
Multivalent antigen-binding proteins
|
PT1047449E
(pt)
|
1997-10-28 |
2004-04-30 |
Univ British Columbia |
Composicoes imunologicas e metodos de utilizacao para alterar transitoriamente a mielina do sistema nervoso central mamifero para promover a regeneracao neuronal
|
DK1049787T3
(da)
|
1998-01-23 |
2005-04-04 |
Vlaams Interuniv Inst Biotech |
Antistofderivater med flere anvendelsesmuligheder
|
IL137409A0
(en)
|
1998-02-09 |
2001-07-24 |
Genentech Inc |
Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same
|
US20040040047A1
(en)
|
1998-03-30 |
2004-02-26 |
Spencer David M. |
Regulated apoptosis using chemically induced dimerization of apoptosis factors
|
CZ121599A3
(cs)
|
1998-04-09 |
1999-10-13 |
Aventis Pharma Deutschland Gmbh |
Jednořetězcová molekula vázající několik antigenů, způsob její přípravy a léčivo obsahující tuto molekulu
|
CA2328725A1
(en)
|
1998-04-15 |
1999-10-21 |
Brigham & Women's Hospital, Inc. |
T cell inhibitory receptor compositions and uses thereof
|
DE19819846B4
(de)
|
1998-05-05 |
2016-11-24 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Multivalente Antikörper-Konstrukte
|
GB9809658D0
(en)
|
1998-05-06 |
1998-07-01 |
Celltech Therapeutics Ltd |
Biological products
|
GB9812545D0
(en)
|
1998-06-10 |
1998-08-05 |
Celltech Therapeutics Ltd |
Biological products
|
WO2000006605A2
(en)
|
1998-07-28 |
2000-02-10 |
Micromet Ag |
Heterominibodies
|
EP1109921A4
(en)
|
1998-09-04 |
2002-08-28 |
Sloan Kettering Inst Cancer |
FOR PROSTATE-SPECIFIC MEMBRANE-ANTI-SPECIFIC FUSION RECEPTORS AND THEIR USE
|
WO2000023573A2
(en)
*
|
1998-10-20 |
2000-04-27 |
City Of Hope |
Cd20-specific redirected t cells and their use in cellular immunotherapy of cd20+ malignancies
|
US6333396B1
(en)
|
1998-10-20 |
2001-12-25 |
Enzon, Inc. |
Method for targeted delivery of nucleic acids
|
JP2002541845A
(ja)
|
1999-04-16 |
2002-12-10 |
セルテック セラピューティックス リミテッド |
合成膜貫通成分
|
US7534866B2
(en)
|
2005-10-19 |
2009-05-19 |
Ibc Pharmaceuticals, Inc. |
Methods and compositions for generating bioactive assemblies of increased complexity and uses
|
US7527787B2
(en)
|
2005-10-19 |
2009-05-05 |
Ibc Pharmaceuticals, Inc. |
Multivalent immunoglobulin-based bioactive assemblies
|
CA2378179A1
(en)
|
1999-07-12 |
2001-01-18 |
Genentech, Inc. |
Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs
|
AU1086501A
(en)
|
1999-10-15 |
2001-04-30 |
Carnegie Institution Of Washington |
Rna interference pathway genes as tools for targeted genetic interference
|
GB9925848D0
(en)
|
1999-11-01 |
1999-12-29 |
Celltech Therapeutics Ltd |
Biological products
|
US6326193B1
(en)
|
1999-11-05 |
2001-12-04 |
Cambria Biosciences, Llc |
Insect control agent
|
CA2391129A1
(en)
|
1999-11-10 |
2001-05-17 |
The Uab Research Foundation |
Lentiviral vector transduction of hematopoietic stem cells
|
US7572631B2
(en)
|
2000-02-24 |
2009-08-11 |
Invitrogen Corporation |
Activation and expansion of T cells
|
ATE373078T1
(de)
|
2000-02-24 |
2007-09-15 |
Xcyte Therapies Inc |
Gleichzeitige stimulation und konzentration von zellen
|
US6867041B2
(en)
|
2000-02-24 |
2005-03-15 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
US6797514B2
(en)
|
2000-02-24 |
2004-09-28 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
NZ521540A
(en)
|
2000-04-11 |
2004-09-24 |
Genentech Inc |
Multivalent antibodies and uses therefor
|
AU2001264946A1
(en)
|
2000-05-24 |
2001-12-03 |
Imclone Systems Incorporated |
Bispecific immunoglobulin-like antigen binding proteins and method of production
|
IL136511A0
(en)
|
2000-06-01 |
2001-06-14 |
Gavish Galilee Bio Appl Ltd |
Genetically engineered mhc molecules
|
AU2001275474A1
(en)
|
2000-06-12 |
2001-12-24 |
Akkadix Corporation |
Materials and methods for the control of nematodes
|
EP1294904A1
(en)
|
2000-06-30 |
2003-03-26 |
Vlaams Interuniversitair Instituut voor Biotechnologie vzw. |
Heterodimeric fusion proteins
|
WO2002008293A2
(en)
|
2000-07-25 |
2002-01-31 |
Immunomedics Inc. |
Multivalent target binding protein
|
GB0025307D0
(en)
|
2000-10-16 |
2000-11-29 |
Celltech Chiroscience Ltd |
Biological products
|
KR100870123B1
(ko)
|
2000-10-20 |
2008-11-25 |
츄가이 세이야꾸 가부시키가이샤 |
저분자화 아고니스트 항체
|
AU2001297703B2
(en)
|
2000-11-07 |
2006-10-19 |
City Of Hope |
CD19-specific redirected immune cells
|
US7829084B2
(en)
|
2001-01-17 |
2010-11-09 |
Trubion Pharmaceuticals, Inc. |
Binding constructs and methods for use thereof
|
WO2002072635A2
(en)
|
2001-03-13 |
2002-09-19 |
University College London |
Specific binding members
|
US7070995B2
(en)
|
2001-04-11 |
2006-07-04 |
City Of Hope |
CE7-specific redirected immune cells
|
CN1294148C
(zh)
|
2001-04-11 |
2007-01-10 |
中国科学院遗传与发育生物学研究所 |
环状单链三特异抗体
|
CA2445746C
(en)
|
2001-04-30 |
2012-09-18 |
City Of Hope |
Chimeric immunoreceptor useful in treating human cancers
|
US7514537B2
(en)
|
2001-04-30 |
2009-04-07 |
City Of Hope |
Chimeric immunoreceptor useful in treating human gliomas
|
US20090257994A1
(en)
|
2001-04-30 |
2009-10-15 |
City Of Hope |
Chimeric immunoreceptor useful in treating human cancers
|
DE60237282D1
(de)
|
2001-06-28 |
2010-09-23 |
Domantis Ltd |
Doppelspezifischer ligand und dessen verwendung
|
US6833441B2
(en)
|
2001-08-01 |
2004-12-21 |
Abmaxis, Inc. |
Compositions and methods for generating chimeric heteromultimers
|
CA2457636C
(en)
|
2001-08-10 |
2012-01-03 |
Aberdeen University |
Antigen binding domains
|
ATE346866T1
(de)
|
2001-09-14 |
2006-12-15 |
Affimed Therapeutics Ag |
Multimerische, einzelkettige, tandem-fv- antikörper
|
AU2002330162B2
(en)
|
2001-10-01 |
2008-08-07 |
Takeda Pharmaceutical Company Limited |
Multi-chain eukaryotic display vectors and uses thereof
|
US20030148982A1
(en)
|
2001-11-13 |
2003-08-07 |
Brenner Malcolm K. |
Bi-spcific chimeric T cells
|
AU2002357072A1
(en)
|
2001-12-07 |
2003-06-23 |
Centocor, Inc. |
Pseudo-antibody constructs
|
US7638326B2
(en)
|
2002-01-03 |
2009-12-29 |
The Trustees Of The University Of Pennsylvania |
Activation and expansion of T-cells using an engineered multivalent signaling platform
|
US7638325B2
(en)
|
2002-01-03 |
2009-12-29 |
The Trustees Of The University Of Pennsylvania |
Activation and expansion of T-cells using an engineered multivalent signaling platform
|
US7745140B2
(en)
|
2002-01-03 |
2010-06-29 |
The Trustees Of The University Of Pennsylvania |
Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
|
CN100522967C
(zh)
|
2002-02-01 |
2009-08-05 |
阿里亚德基因治疗公司 |
含磷化合物及其应用
|
US20040018557A1
(en)
|
2002-03-01 |
2004-01-29 |
Immunomedics, Inc. |
Bispecific antibody point mutations for enhancing rate of clearance
|
GB0208104D0
(en)
|
2002-04-09 |
2002-05-22 |
Univ Dundee |
Method
|
ATE512989T1
(de)
|
2002-04-15 |
2011-07-15 |
Chugai Pharmaceutical Co Ltd |
Verfahren zur herstellung von scdb-bibliotheken
|
TWI275390B
(en)
|
2002-04-30 |
2007-03-11 |
Wyeth Corp |
Process for the preparation of 7-substituted-3- quinolinecarbonitriles
|
US7446190B2
(en)
|
2002-05-28 |
2008-11-04 |
Sloan-Kettering Institute For Cancer Research |
Nucleic acids encoding chimeric T cell receptors
|
PT1517921E
(pt)
|
2002-06-28 |
2006-09-29 |
Domantis Ltd |
Ligandos duplamente especificos com semi-vida no soro aumentada
|
US20040047858A1
(en)
|
2002-09-11 |
2004-03-11 |
Blumberg Richard S. |
Therapeutic anti-BGP(C-CAM1) antibodies and uses thereof
|
JP4511943B2
(ja)
|
2002-12-23 |
2010-07-28 |
ワイス エルエルシー |
Pd−1に対する抗体およびその使用
|
GB0230203D0
(en)
|
2002-12-27 |
2003-02-05 |
Domantis Ltd |
Fc fusion
|
US20050129671A1
(en)
|
2003-03-11 |
2005-06-16 |
City Of Hope |
Mammalian antigen-presenting T cells and bi-specific T cells
|
GB0305702D0
(en)
|
2003-03-12 |
2003-04-16 |
Univ Birmingham |
Bispecific antibodies
|
US20050003403A1
(en)
|
2003-04-22 |
2005-01-06 |
Rossi Edmund A. |
Polyvalent protein complex
|
US7402431B2
(en)
|
2004-03-01 |
2008-07-22 |
Immunovative Therapies, Ltd. |
T-cell therapy formulation
|
BRPI0410785A
(pt)
|
2003-05-23 |
2006-06-20 |
Wyeth Corp |
molécula de ácido nucleico isolada, célula hospedeira, animal transgênico não humano, proteìna isolada, oligonucleotìdeo anti-sentido, molécula de sirna, anticorpo isolado, métodos de triagem quanto aos compostos de teste capazes de inibir, de intensificar ou imitar a interação do gitrl com o gitr, para diagnosticar doenças, para tratar um paciente em risco ou diagnosticado com uma doença, para induzir e para inibir a proliferação de uma população celular contendo células t efetoras, de bloquear a supressão e de supressão de uma população celular que inclua células t efetoras na presença de células t reguladoras cd4+cd25+, e para tratar uma doença, composição farmacêutica, e, adjuvante de vacina
|
AU2004252170B2
(en)
|
2003-06-27 |
2011-01-27 |
Biogen Ma Inc. |
Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
|
JP5026072B2
(ja)
|
2003-07-01 |
2012-09-12 |
イミューノメディクス、インコーポレイテッド |
二重特異性抗体の多価キャリヤー
|
US20050048054A1
(en)
|
2003-07-11 |
2005-03-03 |
Shino Hanabuchi |
Lymphocytes; methods
|
US7696322B2
(en)
|
2003-07-28 |
2010-04-13 |
Catalent Pharma Solutions, Inc. |
Fusion antibodies
|
WO2005042743A2
(en)
|
2003-08-18 |
2005-05-12 |
Medimmune, Inc. |
Humanization of antibodies
|
WO2005019429A2
(en)
|
2003-08-22 |
2005-03-03 |
Potentia Pharmaceuticals, Inc. |
Compositions and methods for enhancing phagocytosis or phagocyte activity
|
WO2005035575A2
(en)
|
2003-08-22 |
2005-04-21 |
Medimmune, Inc. |
Humanization of antibodies
|
AU2004279742A1
(en)
|
2003-10-08 |
2005-04-21 |
Kyowa Hakko Kirin Co., Ltd. |
Fused protein composition
|
US7435596B2
(en)
|
2004-11-04 |
2008-10-14 |
St. Jude Children's Research Hospital, Inc. |
Modified cell line and method for expansion of NK cell
|
US20050113564A1
(en)
|
2003-11-05 |
2005-05-26 |
St. Jude Children's Research Hospital |
Chimeric receptors with 4-1BB stimulatory signaling domain
|
US7220755B2
(en)
|
2003-11-12 |
2007-05-22 |
Biosensors International Group, Ltd. |
42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same
|
AU2004293471C1
(en)
*
|
2003-11-25 |
2011-02-24 |
The Government Of The United States, As Represented By The Secretary Of Health And Human Services |
Mutated anti-CD22 antibodies and immunoconjugates
|
EP1692318A4
(en)
|
2003-12-02 |
2008-04-02 |
Genzyme Corp |
COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF LUNG CANCER
|
WO2005062916A2
(en)
|
2003-12-22 |
2005-07-14 |
Centocor, Inc. |
Methods for generating multimeric molecules
|
GB0329825D0
(en)
|
2003-12-23 |
2004-01-28 |
Celltech R&D Ltd |
Biological products
|
US20050266425A1
(en)
|
2003-12-31 |
2005-12-01 |
Vaccinex, Inc. |
Methods for producing and identifying multispecific antibodies
|
US8383575B2
(en)
|
2004-01-30 |
2013-02-26 |
Paul Scherrer Institut |
(DI)barnase-barstar complexes
|
GB0409799D0
(en)
|
2004-04-30 |
2004-06-09 |
Isis Innovation |
Method of generating improved immune response
|
ES2653570T3
(es)
|
2004-05-27 |
2018-02-07 |
The Trustees Of The University Of Pennsylvania |
Células presentadoras de antígeno artificiales novedosas y usos de las mismas
|
EP1765402A2
(en)
|
2004-06-04 |
2007-03-28 |
Duke University |
Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity
|
JP2008512352A
(ja)
|
2004-07-17 |
2008-04-24 |
イムクローン システムズ インコーポレイティド |
新規な四価の二重特異性抗体
|
AU2005282700A1
(en)
|
2004-09-02 |
2006-03-16 |
Genentech, Inc. |
Heteromultimeric molecules
|
WO2006036445A2
(en)
|
2004-09-24 |
2006-04-06 |
Trustees Of Dartmouth College |
Chimeric nk receptor and methods for treating cancer
|
WO2006060878A1
(en)
|
2004-12-10 |
2006-06-15 |
Peter Maccallum Cancer Institute |
Methods and compositions for adoptive immunotherapy
|
PT1866339E
(pt)
|
2005-03-25 |
2013-09-03 |
Gitr Inc |
Moléculas de ligação a gitr e suas utilizações
|
EP3050963B1
(en)
|
2005-03-31 |
2019-09-18 |
Chugai Seiyaku Kabushiki Kaisha |
Process for production of polypeptide by regulation of assembly
|
CA2604032C
(en)
|
2005-04-06 |
2017-08-22 |
Ibc Pharmaceuticals, Inc. |
Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
|
US9296816B2
(en)
|
2005-04-15 |
2016-03-29 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
EP2418278A3
(en)
|
2005-05-09 |
2012-07-04 |
Ono Pharmaceutical Co., Ltd. |
Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
|
EP1899364B1
(en)
|
2005-05-17 |
2020-02-19 |
University of Connecticut |
Compositions and methods for immunomodulation in an organism
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
US20060263367A1
(en)
|
2005-05-23 |
2006-11-23 |
Fey Georg H |
Bispecific antibody devoid of Fc region and method of treatment using same
|
AU2006265108C1
(en)
|
2005-07-01 |
2013-01-17 |
E. R. Squibb & Sons, L.L.C. |
Human monoclonal antibodies to programmed death ligand 1 (PD-L1)
|
US20070036773A1
(en)
|
2005-08-09 |
2007-02-15 |
City Of Hope |
Generation and application of universal T cells for B-ALL
|
NZ612578A
(en)
|
2005-08-19 |
2014-11-28 |
Abbvie Inc |
Dual variable domain immunoglobin and uses thereof
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
DE602005018477D1
(de)
|
2005-08-26 |
2010-02-04 |
Pls Design Gmbh |
Bivalente IgY Antikörperkonstrukte für diagnostische und therapeutische Anwendungen
|
KR20140033237A
(ko)
|
2005-10-07 |
2014-03-17 |
엑셀리시스, 인코포레이티드 |
포스파티딜이노시톨 3-키나아제 억제제 및 이의 사용 방법
|
WO2007044887A2
(en)
|
2005-10-11 |
2007-04-19 |
Transtarget, Inc. |
Method for producing a population of homogenous tetravalent bispecific antibodies
|
US8623356B2
(en)
|
2005-11-29 |
2014-01-07 |
The University Of Sydney |
Demibodies: dimerization-activated therapeutic agents
|
MY147379A
(en)
|
2005-12-02 |
2012-11-30 |
Sinai School Medicine |
Chimeric viruses presenting non-native surface proteins and uses thereof
|
NZ569541A
(en)
|
2006-01-13 |
2012-05-25 |
Us Gov Health & Human Serv |
Codon optimized IL-15 and IL-15R-alpha genes for expression in mammalian cells
|
US20110212086A1
(en)
|
2006-01-19 |
2011-09-01 |
Genzyme Corporation |
GITR Antibodies For The Treatment of Cancer
|
EP1986684A2
(en)
|
2006-02-15 |
2008-11-05 |
ImClone Systems Incorporated |
Functional antibodies
|
GEP20135917B
(en)
|
2006-03-17 |
2013-09-10 |
Biogen Idec Inc |
Stabilized polypeptide compositions
|
CA2646965C
(en)
|
2006-03-24 |
2016-06-21 |
Jonathan H. Davis |
Engineered heterodimeric protein domains
|
WO2007112362A2
(en)
|
2006-03-24 |
2007-10-04 |
The Regents Of The University Of California |
Construction of a multivalent scfv through alkyne-azide 1,3-dipolar cycloaddition
|
DK2009101T3
(en)
|
2006-03-31 |
2018-01-15 |
Chugai Pharmaceutical Co Ltd |
Antibody modification method for purification of a bispecific antibody
|
EP2027153B1
(en)
|
2006-05-25 |
2014-04-30 |
Bayer Intellectual Property GmbH |
Dimeric molecular complexes
|
US20070274985A1
(en)
|
2006-05-26 |
2007-11-29 |
Stefan Dubel |
Antibody
|
WO2007146968A2
(en)
|
2006-06-12 |
2007-12-21 |
Trubion Pharmaceuticals, Inc. |
Single-chain multivalent binding proteins with effector function
|
EP2051734B1
(en)
|
2006-08-18 |
2016-10-05 |
Armagen Technologies, Inc. |
Agents for blood-brain barrier delivery
|
WO2008027236A2
(en)
|
2006-08-30 |
2008-03-06 |
Genentech, Inc. |
Multispecific antibodies
|
US20100105136A1
(en)
|
2006-10-09 |
2010-04-29 |
The General Hospital Corporation |
Chimeric t-cell receptors and t-cells targeting egfrviii on tumors
|
EP1916259A1
(en)
|
2006-10-26 |
2008-04-30 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Anti-glycoprotein VI SCFV fragment for treatment of thrombosis
|
WO2008140477A2
(en)
|
2006-11-02 |
2008-11-20 |
Capon Daniel J |
Hybrid immunoglobulins with moving parts
|
US20080131415A1
(en)
|
2006-11-30 |
2008-06-05 |
Riddell Stanley R |
Adoptive transfer of cd8 + t cell clones derived from central memory cells
|
WO2008140621A2
(en)
|
2006-12-21 |
2008-11-20 |
Mount Sinai School Of Medicine Of New York University |
Transgenic oncolytic viruses and uses thereof
|
CA2584494A1
(en)
|
2007-03-27 |
2008-09-27 |
Jeffrey A. Medin |
Vector encoding therapeutic polypeptide and safety elements to clear transduced cells
|
MX2009010282A
(es)
|
2007-03-29 |
2009-10-12 |
Genmab As |
Anticuerpos biespecificos y metodos para su produccion.
|
SI2856876T1
(en)
|
2007-03-30 |
2018-04-30 |
Memorial Sloan-Kettering Cancer Center |
Constituent expression of costimulatory ligands on indirectly transmitted T lymphocytes
|
US20080260738A1
(en)
|
2007-04-18 |
2008-10-23 |
Moore Margaret D |
Single chain fc, methods of making and methods of treatment
|
BRPI0812562A2
(pt)
|
2007-06-12 |
2019-09-24 |
Trubion Pharmaceuticals Inc |
composições terapêuticas anti-cd20 e métodos
|
EP3222634A1
(en)
|
2007-06-18 |
2017-09-27 |
Merck Sharp & Dohme B.V. |
Antibodies to human programmed death receptor pd-1
|
NZ582330A
(en)
|
2007-06-27 |
2012-05-25 |
Marinepolymer Tech Inc |
COMPLEXES OF IL-15 AND IL-15Ra (RECEPTOR ALPHA) AND USES THEREOF
|
CA2693677C
(en)
|
2007-07-12 |
2018-02-13 |
Tolerx, Inc. |
Combination therapies employing gitr binding molecules
|
CA2694488A1
(en)
|
2007-07-31 |
2009-02-05 |
Medimmune, Llc |
Multispecific epitope binding proteins and uses thereof
|
CA2696263C
(en)
|
2007-08-15 |
2017-06-13 |
Bing Liu |
Monospecific and multispecific antibodies and method of use
|
EP2212350B1
(en)
|
2007-10-26 |
2013-08-28 |
Governing Council of the University of Toronto |
Treating chronic viral infection by targetting TIM-3
|
KR20100097716A
(ko)
|
2007-11-27 |
2010-09-03 |
아블린쓰 엔.브이. |
이종이량체 사이토킨 및/또는 이의 수용체에 대한 아미노산 서열과 이를 포함하는 폴리펩티드
|
CN101932608A
(zh)
|
2007-11-30 |
2010-12-29 |
葛兰素集团有限公司 |
抗原结合构建体
|
US20090162359A1
(en)
|
2007-12-21 |
2009-06-25 |
Christian Klein |
Bivalent, bispecific antibodies
|
US8242247B2
(en)
|
2007-12-21 |
2012-08-14 |
Hoffmann-La Roche Inc. |
Bivalent, bispecific antibodies
|
US9266967B2
(en)
|
2007-12-21 |
2016-02-23 |
Hoffmann-La Roche, Inc. |
Bivalent, bispecific antibodies
|
US8227577B2
(en)
|
2007-12-21 |
2012-07-24 |
Hoffman-La Roche Inc. |
Bivalent, bispecific antibodies
|
EP2235064B1
(en)
|
2008-01-07 |
2015-11-25 |
Amgen Inc. |
Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
|
WO2009091826A2
(en)
|
2008-01-14 |
2009-07-23 |
The Board Of Regents Of The University Of Texas System |
Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car)
|
US10059923B2
(en)
|
2008-01-30 |
2018-08-28 |
Memorial Sloan Kettering Cancer Center |
Methods for off-the-shelf tumor immunotherapy using allogeneic T-cell precursors
|
PT2242773T
(pt)
|
2008-02-11 |
2017-09-15 |
Cure Tech Ltd |
Anticorpos monoclonais para o tratamento de tumores
|
WO2009104019A1
(en)
|
2008-02-21 |
2009-08-27 |
Astrazeneca Ab |
Combination therapy 238
|
US8379824B2
(en)
|
2008-03-06 |
2013-02-19 |
At&T Intellectual Property I, Lp |
Methods and apparatus to provide a network-based caller identification service in a voice over internet protocol network
|
US8168757B2
(en)
|
2008-03-12 |
2012-05-01 |
Merck Sharp & Dohme Corp. |
PD-1 binding proteins
|
CN107198772A
(zh)
|
2008-03-25 |
2017-09-26 |
罗氏格黎卡特股份公司 |
Ii型抗cd20抗体与环磷酰胺、长春新碱和多柔比星联合治疗非霍奇金淋巴瘤的应用
|
CA2729810A1
(en)
|
2008-07-02 |
2010-01-07 |
Emergent Product Development Seattle, Llc |
Tgf-.beta. antagonist multi-target binding proteins
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
RS54233B1
(en)
|
2008-08-25 |
2015-12-31 |
Amplimmune Inc. |
PD-1 ANTAGONIST COMPOSITIONS AND PROCEDURES FOR THEIR APPLICATION
|
CN102203125A
(zh)
|
2008-08-25 |
2011-09-28 |
安普利穆尼股份有限公司 |
Pd-1拮抗剂及其使用方法
|
ES2899174T3
(es)
|
2008-08-26 |
2022-03-10 |
Hope City |
Método y composiciones para el funcionamiento mejorado del efecto antitumoral de las células T
|
WO2010030002A1
(ja)
|
2008-09-12 |
2010-03-18 |
国立大学法人三重大学 |
外来性gitrリガンド発現細胞
|
US8476282B2
(en)
|
2008-11-03 |
2013-07-02 |
Intellikine Llc |
Benzoxazole kinase inhibitors and methods of use
|
PE20120341A1
(es)
|
2008-12-09 |
2012-04-24 |
Genentech Inc |
Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t
|
WO2010085660A2
(en)
|
2009-01-23 |
2010-07-29 |
Roger Williams Hospital |
Viral vectors encoding multiple highly homologous non-viral polypeptides and the use of same
|
BRPI1007371A2
(pt)
|
2009-01-29 |
2018-03-27 |
Abbott Lab |
proteínas de ligação a il-1
|
WO2010091262A1
(en)
|
2009-02-05 |
2010-08-12 |
Mount Sinai School Of Medicine Of New York University |
Chimeric newcastle disease viruses and uses thereof
|
EP3192811A1
(en)
|
2009-02-09 |
2017-07-19 |
Université d'Aix-Marseille |
Pd-1 antibodies and pd-l1 antibodies and uses thereof
|
JP2012518404A
(ja)
|
2009-02-23 |
2012-08-16 |
グレンマーク・ファーマシューティカルズ・エスエー |
Cd19に結合するヒト化抗体及びその使用
|
DK2414362T3
(da)
|
2009-04-03 |
2014-09-22 |
Verastem Inc |
Pyrimidinsubstituerede purinforbindelser som kinaseinhibitorer
|
CA2759233C
(en)
|
2009-04-27 |
2019-07-16 |
Oncomed Pharmaceuticals, Inc. |
Method for making heteromultimeric molecules
|
LT2990421T
(lt)
|
2009-04-30 |
2018-04-25 |
Tel Hashomer Medical Research Infrastructure And Services Ltd. |
Anti-ceacam1 antikūnai ir jų panaudojimo būdai
|
WO2011020047A1
(en)
|
2009-08-14 |
2011-02-17 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Use of il-15 to increase thymic output and to treat lymphopenia
|
AU2010289677B2
(en)
|
2009-09-03 |
2014-07-31 |
Merck Sharp & Dohme Llc |
Anti-GITR antibodies
|
JP5934099B2
(ja)
|
2009-10-01 |
2016-06-15 |
アメリカ合衆国 |
抗血管内皮増殖因子受容体−2キメラ抗原受容体及び癌の治療のためのその使用
|
US9181527B2
(en)
|
2009-10-29 |
2015-11-10 |
The Trustees Of Dartmouth College |
T cell receptor-deficient T cell compositions
|
GB0919054D0
(en)
|
2009-10-30 |
2009-12-16 |
Isis Innovation |
Treatment of obesity
|
US20130017199A1
(en)
|
2009-11-24 |
2013-01-17 |
AMPLIMMUNE ,Inc. a corporation |
Simultaneous inhibition of pd-l1/pd-l2
|
WO2011090762A1
(en)
|
2009-12-29 |
2011-07-28 |
Emergent Product Development Seattle, Llc |
Heterodimer binding proteins and uses thereof
|
JP5894538B2
(ja)
|
2010-02-04 |
2016-03-30 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
炎症性ヒトTh17細胞の増殖および機能を決定的に調節するICOS
|
KR102152109B1
(ko)
|
2010-04-20 |
2020-09-07 |
젠맵 에이/에스 |
이종이량체 항체 fc-함유 단백질 및 그의 생산 방법
|
US9089520B2
(en)
|
2010-05-21 |
2015-07-28 |
Baylor College Of Medicine |
Methods for inducing selective apoptosis
|
US9242014B2
(en)
|
2010-06-15 |
2016-01-26 |
The Regents Of The University Of California |
Receptor tyrosine kinase-like orphan receptor 1 (ROR1) single chain Fv antibody fragment conjugates and methods of use thereof
|
WO2011159877A2
(en)
|
2010-06-18 |
2011-12-22 |
The Brigham And Women's Hospital, Inc. |
Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
|
AR084469A1
(es)
|
2010-07-09 |
2013-05-22 |
Exelixis Inc |
Combinaciones de inhibidores de quinasas para el tratamiento del cancer
|
RU2013106427A
(ru)
|
2010-07-16 |
2014-08-27 |
Пирамал Энтерпрайзис Лимитед |
Замещенные имидазохинолиновые производные в качестве ингибиторов киназы
|
MX2013004792A
(es)
|
2010-10-27 |
2013-08-27 |
Baylor College Medicine |
Receptor cd27 quimericos para redirigir celulas t a malignidades cd70-positivas.
|
LT2649086T
(lt)
|
2010-12-09 |
2017-11-10 |
The Trustees Of The University Of Pennsylvania |
Chimeriniu antigenų receptoriumi modifikuotų ląstelių naudojimas vėžio gydymui
|
CA2821080C
(en)
|
2010-12-14 |
2021-02-02 |
University Of Maryland, Baltimore |
Universal anti-tag chimeric antigen receptor-expressing t cells and methods of treating cancer
|
CA2824997C
(en)
|
2011-01-18 |
2023-01-17 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treating cancer
|
RU2688185C2
(ru)
|
2011-03-23 |
2019-05-21 |
Фред Хатчинсон Кэнсер Рисерч Сентер |
Способ и композиции для клеточной иммунотерапии
|
WO2012127464A2
(en)
|
2011-03-23 |
2012-09-27 |
Gavish-Galilee Bio Applications Ltd |
Constitutively activated t cells for use in adoptive cell therapy
|
ES2785081T3
(es)
|
2011-04-01 |
2020-10-05 |
Memorial Sloan Kettering Cancer Center |
Anticuerpos biespecíficos similares a receptores de células T específicos para un péptido de WT1 presentado por HLA-A2
|
WO2012138858A1
(en)
|
2011-04-08 |
2012-10-11 |
Baylor College Of Medicine |
Reversing the effects of the tumor microenvironment using chimeric cytokine receptors
|
CN107188969B
(zh)
|
2011-04-08 |
2021-08-27 |
美国卫生和人力服务部 |
抗-表皮生长因子受体变体iii嵌合抗原受体及其用于治疗癌症的用途
|
US20130071414A1
(en)
|
2011-04-27 |
2013-03-21 |
Gianpietro Dotti |
Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies
|
US8841418B2
(en)
|
2011-07-01 |
2014-09-23 |
Cellerant Therapeutics, Inc. |
Antibodies that specifically bind to TIM3
|
WO2013016352A1
(en)
|
2011-07-25 |
2013-01-31 |
Nationwide Children's Hospital, Inc. |
Recombinant virus products and methods for inhibition of expression of dux4
|
CN114835823A
(zh)
|
2011-07-29 |
2022-08-02 |
宾夕法尼亚大学董事会 |
转换共刺激受体
|
SG2014009492A
(en)
|
2011-08-11 |
2014-09-26 |
Intellikine Llc |
Kinase inhibitor polymorphs
|
US9833476B2
(en)
|
2011-08-31 |
2017-12-05 |
The Trustees Of Dartmouth College |
NKP30 receptor targeted therapeutics
|
US20130108641A1
(en)
|
2011-09-14 |
2013-05-02 |
Sanofi |
Anti-gitr antibodies
|
US20140255363A1
(en)
|
2011-09-16 |
2014-09-11 |
Baylor College Of Medicine |
Targeting the tumor microenvironment using manipulated nkt cells
|
EA201490636A1
(ru)
|
2011-09-16 |
2014-08-29 |
Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания |
Сконструированные с помощью рнк t-клетки для лечения злокачественных новообразований
|
WO2013054320A1
(en)
|
2011-10-11 |
2013-04-18 |
Tel Hashomer Medical Research Infrastructure And Services Ltd. |
Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
|
CA2851795C
(en)
|
2011-10-20 |
2018-11-13 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-cd22 chimeric antigen receptors
|
SG10201805291TA
(en)
|
2011-10-27 |
2018-08-30 |
Genmab As |
Production of heterodimeric proteins
|
US9556271B2
(en)
|
2011-12-01 |
2017-01-31 |
The Brigham And Women's Hospital, Inc. |
Anti-CEACAM1 recombinant antibodies for cancer therapy
|
EP2814846B1
(en)
|
2012-02-13 |
2020-01-08 |
Seattle Children's Hospital d/b/a Seattle Children's Research Institute |
Bispecific chimeric antigen receptors and therapeutic uses thereof
|
JP2015513399A
(ja)
|
2012-02-22 |
2015-05-14 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
癌の治療のために有用なt細胞の存続的集団を作製するための組成物および方法
|
EP4275699A3
(en)
|
2012-02-22 |
2024-01-03 |
The Trustees of the University of Pennsylvania |
Use of the cd2 signaling domain in second-generation chimeric antigen receptors
|
KR20140135715A
(ko)
|
2012-02-22 |
2014-11-26 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
항종양 활성 및 car 지속을 증진시키기 위한 icos 기반 car의 용도
|
EP4289948A3
(en)
|
2012-05-25 |
2024-04-17 |
The Regents of the University of California |
Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
|
CA2878856A1
(en)
|
2012-07-13 |
2014-01-16 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for regulating car t cells
|
MX2015000426A
(es)
|
2012-07-13 |
2015-07-14 |
Univ Pennsylvania |
Incremento de actividad de celulas t car mediante cointroduccion de un anticuerpo biespecifico.
|
IN2014DN11156A
(ja)
|
2012-07-13 |
2015-10-02 |
Univ Pennsylvania |
|
WO2014011993A2
(en)
|
2012-07-13 |
2014-01-16 |
The Trustees Of The University Of Pennsylvania |
Epitope spreading associated with car t-cells
|
PT4019041T
(pt)
|
2012-07-13 |
2023-03-29 |
Childrens Hospital Philadelphia |
Gestão de toxicidade para atividade antitumoral de cars
|
US20150290244A1
(en)
|
2012-07-13 |
2015-10-15 |
The Trustees Of The University Of Pennsylvania |
Use of cart19 to deplete normal b cells to induce tolerance
|
JP2015525781A
(ja)
|
2012-07-31 |
2015-09-07 |
ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドThe Brigham and Women’s Hospital, Inc. |
免疫応答の調節
|
RU2019126655A
(ru)
|
2012-08-20 |
2019-11-12 |
Фред Хатчинсон Кансэр Рисёч Сентер |
Нуклеиновые кислоты, кодирующие химерные рецепторы, полипептидные химерные рецепторы, кодируемые ими, векторы экспрессии, содержащие их, выделенные клетки-хозяева, содержащие их, композиции, содержащие выделенные клетки-хозяева, а также способы получения выделенных клеток-хозяев in vitro, способы выбора нуклеиновых кислот, кодирующих химерные рецепторы, in vitro и способы проведения клеточной иммунотерапии у субъекта, имеющего опухоль
|
WO2014039513A2
(en)
|
2012-09-04 |
2014-03-13 |
The Trustees Of The University Of Pennsylvania |
Inhibition of diacylglycerol kinase to augment adoptive t cell transfer
|
TW201414837A
(zh)
|
2012-10-01 |
2014-04-16 |
Univ Pennsylvania |
標定基質細胞以治療癌症之組合物和方法
|
US10117896B2
(en)
|
2012-10-05 |
2018-11-06 |
The Trustees Of The University Of Pennsylvania |
Use of a trans-signaling approach in chimeric antigen receptors
|
US20150273056A1
(en)
|
2012-10-12 |
2015-10-01 |
The Brigham And Women's Hospital, Inc. |
Enhancement of the immune response
|
US20160008399A1
(en)
|
2013-01-14 |
2016-01-14 |
Fred Hutchinson Cancer Research Center |
Compositions and methods for delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse
|
EP3881868B1
(en)
|
2013-02-15 |
2023-09-27 |
The Regents Of The University Of California |
Chimeric antigen receptor and methods of use thereof
|
CA2901960C
(en)
|
2013-02-20 |
2022-10-04 |
Novartis Ag |
Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
|
US9573988B2
(en)
|
2013-02-20 |
2017-02-21 |
Novartis Ag |
Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells
|
EP3241897B1
(en)
|
2013-03-07 |
2018-10-03 |
Baylor College of Medicine |
Targeting cd138 in cancer
|
US9434935B2
(en)
|
2013-03-10 |
2016-09-06 |
Bellicum Pharmaceuticals, Inc. |
Modified caspase polypeptides and uses thereof
|
EA038981B1
(ru)
|
2013-03-14 |
2021-11-17 |
Икан Скул Оф Медсин Эт Маунт Синай |
Вирусы болезни ньюкасла и их применение
|
CN105209065B
(zh)
|
2013-03-14 |
2020-07-31 |
贝里坤制药股份有限公司 |
控制t细胞增殖的方法
|
ES2769574T3
(es)
|
2013-03-15 |
2020-06-26 |
Michael C Milone |
Reconocimiento de células citotóxicas con receptores quiméricos para inmunoterapia adoptiva
|
TWI654206B
(zh)
|
2013-03-16 |
2019-03-21 |
諾華公司 |
使用人類化抗-cd19嵌合抗原受體治療癌症
|
EP3569253A1
(en)
|
2013-06-05 |
2019-11-20 |
Bellicum Pharmaceuticals, Inc. |
Methods for inducing partial apoptosis using caspase polypeptides
|
KR20160084438A
(ko)
|
2013-11-13 |
2016-07-13 |
노파르티스 아게 |
면역 반응을 강화하기 위한 mTOR 억제제
|
DK3071222T3
(da)
|
2013-11-21 |
2020-11-16 |
Ucl Business Ltd |
Celle
|
US9512084B2
(en)
|
2013-11-29 |
2016-12-06 |
Novartis Ag |
Amino pyrimidine derivatives
|
CN116478927A
(zh)
|
2013-12-19 |
2023-07-25 |
诺华股份有限公司 |
人间皮素嵌合抗原受体及其用途
|
JP6793902B2
(ja)
|
2013-12-20 |
2020-12-02 |
ノバルティス アーゲー |
調節可能キメラ抗原受容体
|
ES2963718T3
(es)
|
2014-01-21 |
2024-04-01 |
Novartis Ag |
Capacidad presentadora de antígenos de células CAR-T potenciada mediante introducción conjunta de moléculas co-estimuladoras
|
EP3119423B1
(en)
|
2014-03-15 |
2022-12-14 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor
|
EP3811970A1
(en)
|
2014-03-15 |
2021-04-28 |
Novartis AG |
Regulatable chimeric antigen receptor
|
KR20240042250A
(ko)
|
2014-04-07 |
2024-04-01 |
노파르티스 아게 |
항-cd19 키메라 항원 수용체를 사용한 암의 치료
|
US20170274014A1
(en)
|
2014-07-21 |
2017-09-28 |
Jennifer Brogdon |
Combinations of low, immune enhancing, doses of mtor inhibitors and cars
|
JP2017528433A
(ja)
|
2014-07-21 |
2017-09-28 |
ノバルティス アーゲー |
低い免疫増強用量のmTOR阻害剤とCARの組み合わせ
|
MX2017001011A
(es)
|
2014-07-21 |
2018-05-28 |
Novartis Ag |
Tratamiento de cancer de usando un receptor quimerico de antigeno anti-bcma.
|
MX2017001013A
(es)
|
2014-07-21 |
2018-02-21 |
Novartis Ag |
Tratamiento de cáncer usando un receptor quimérico de antígeno cll-1.
|
EP3722316A1
(en)
|
2014-07-21 |
2020-10-14 |
Novartis AG |
Treatment of cancer using a cd33 chimeric antigen receptor
|
US20170226495A1
(en)
|
2014-07-21 |
2017-08-10 |
Novartis Ag |
Sortase molecules and uses thereof
|
US11542488B2
(en)
|
2014-07-21 |
2023-01-03 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
ES2781175T3
(es)
|
2014-07-31 |
2020-08-31 |
Novartis Ag |
Subconjunto optimizado de células T que contienen un receptor de antígeno quimérico
|
EP3180359A1
(en)
|
2014-08-14 |
2017-06-21 |
Novartis AG |
Treatment of cancer using gfr alpha-4 chimeric antigen receptor
|
HUE049218T2
(hu)
|
2014-08-19 |
2020-10-28 |
Novartis Ag |
Anti-CD123 kiméra antigénreceptor (CAR) rák kezelésében történõ alkalmazásra
|
DK3194443T3
(da)
|
2014-09-17 |
2021-09-27 |
Novartis Ag |
Målretning af cytotoksiske celler med kimære receptorer i forbindelse med adoptiv immunterapi
|
CN106973568B
(zh)
|
2014-10-08 |
2021-07-23 |
诺华股份有限公司 |
预测针对嵌合抗原受体疗法的治疗应答性的生物标志及其用途
|
WO2016061368A1
(en)
|
2014-10-15 |
2016-04-21 |
The Children's Hospital Of Philadelphia |
Compositions and methods for treating b-lymphoid malignancies
|
EP3240805A4
(en)
|
2014-12-15 |
2018-05-09 |
The Regents of the University of California |
Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20
|
JP6633081B2
(ja)
|
2014-12-24 |
2020-01-22 |
ユーシーエル ビジネス リミテッド |
細胞
|
AU2015374296B2
(en)
|
2014-12-29 |
2021-09-02 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
US11459390B2
(en)
|
2015-01-16 |
2022-10-04 |
Novartis Ag |
Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor
|
US11161907B2
(en)
|
2015-02-02 |
2021-11-02 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
US20180140602A1
(en)
|
2015-04-07 |
2018-05-24 |
Novartis Ag |
Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
|
KR20170134642A
(ko)
|
2015-04-08 |
2017-12-06 |
노파르티스 아게 |
Cd20 요법, cd22 요법, 및 cd19 키메라 항원 수용체 (car) - 발현 세포와의 조합 요법
|
WO2016168595A1
(en)
|
2015-04-17 |
2016-10-20 |
Barrett David Maxwell |
Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
|
US20180298068A1
(en)
|
2015-04-23 |
2018-10-18 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
WO2017015427A1
(en)
|
2015-07-21 |
2017-01-26 |
Novartis Ag |
Methods for improving the efficacy and expansion of immune cells
|
US11667691B2
(en)
|
2015-08-07 |
2023-06-06 |
Novartis Ag |
Treatment of cancer using chimeric CD3 receptor proteins
|
EP3344996A2
(en)
|
2015-09-03 |
2018-07-11 |
The Trustees Of The University Of Pennsylvania |
Biomarkers predictive of cytokine release syndrome
|
SG10202110257UA
(en)
|
2015-09-17 |
2021-10-28 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
CN105924530B
(zh)
*
|
2015-10-13 |
2019-08-06 |
中国人民解放军总医院 |
嵌合抗原受体及其基因和重组表达载体、car20-nkt细胞及其制备方法和应用
|
CA3006432A1
(en)
|
2015-12-04 |
2017-06-08 |
Novartis Ag |
Compositions and methods for immunooncology
|
WO2017112741A1
(en)
|
2015-12-22 |
2017-06-29 |
Novartis Ag |
Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy
|
CN109153975A
(zh)
|
2015-12-28 |
2019-01-04 |
诺华股份有限公司 |
制备嵌合抗原受体表达细胞的方法
|
MX2018008106A
(es)
|
2015-12-30 |
2019-03-14 |
Novartis Ag |
Terapias con celulas inmunoefectoras de una eficacia mejorada.
|
SG11201807489PA
(en)
|
2016-03-04 |
2018-09-27 |
Novartis Ag |
Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
|
WO2017165683A1
(en)
|
2016-03-23 |
2017-09-28 |
Novartis Ag |
Cell secreted minibodies and uses thereof
|
CN105949317B
(zh)
*
|
2016-04-12 |
2019-07-02 |
上海优卡迪生物医药科技有限公司 |
抗cd20嵌合抗原受体、编码基因、重组表达载体及其构建方法和应用
|
ES2944607T3
(es)
|
2016-04-15 |
2023-06-22 |
Novartis Ag |
Composiciones y métodos para la expresión selectiva de receptores quiméricos para el antígeno
|
CN105968210B
(zh)
*
|
2016-05-13 |
2019-05-31 |
深圳生创精准医疗科技有限公司 |
靶向cd22的强杀伤性嵌合抗原受体t细胞及其在制备治疗肿瘤的药物中的用途
|
WO2017210617A2
(en)
|
2016-06-02 |
2017-12-07 |
Porter, David, L. |
Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
|
JP7219376B2
(ja)
|
2016-07-15 |
2023-02-08 |
ノバルティス アーゲー |
キメラ抗原受容体をキナーゼ阻害薬と併用して使用したサイトカイン放出症候群の治療及び予防
|
TW201806619A
(zh)
|
2016-07-28 |
2018-03-01 |
瑞士商諾華公司 |
嵌合抗原受體及pd-1抑制劑之組合療法
|
CA3032581A1
(en)
|
2016-08-01 |
2018-02-08 |
Novartis Ag |
Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
|
CN110582488A
(zh)
|
2016-09-30 |
2019-12-17 |
诺华股份有限公司 |
具有增强功效的免疫效应细胞疗法
|
WO2018067992A1
(en)
|
2016-10-07 |
2018-04-12 |
Novartis Ag |
Chimeric antigen receptors for the treatment of cancer
|
WO2018140725A1
(en)
|
2017-01-26 |
2018-08-02 |
Novartis Ag |
Cd28 compositions and methods for chimeric antigen receptor therapy
|
JP2020506700A
(ja)
|
2017-01-31 |
2020-03-05 |
ノバルティス アーゲー |
多重特異性を有するキメラt細胞受容体タンパク質を用いた癌の治療
|
EP3589647A1
(en)
|
2017-02-28 |
2020-01-08 |
Novartis AG |
Shp inhibitor compositions and uses for chimeric antigen receptor therapy
|
EP3600392A1
(en)
|
2017-03-22 |
2020-02-05 |
Novartis AG |
Biomarkers and car t cell therapies with enhanced efficacy
|
EP3615068A1
(en)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
US20200055948A1
(en)
|
2017-04-28 |
2020-02-20 |
Novartis Ag |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
TWI829655B
(zh)
|
2017-10-18 |
2024-01-21 |
瑞士商諾華公司 |
用於選擇性蛋白質降解的組合物及方法
|
EP3700926A1
(en)
|
2017-10-25 |
2020-09-02 |
Novartis AG |
Methods of making chimeric antigen receptor-expressing cells
|
RU2020119365A
(ru)
|
2017-11-15 |
2021-12-13 |
Новартис Аг |
Химерный антигенный рецептор, нацеливающийся на всма, химерный антигенный рецептор, нацеливающийся на cd19, и средства комбинированной терапии
|
AU2018375738A1
(en)
|
2017-11-30 |
2020-06-11 |
Novartis Ag |
BCMA-targeting chimeric antigen receptor, and uses thereof
|
WO2019136432A1
(en)
|
2018-01-08 |
2019-07-11 |
Novartis Ag |
Immune-enhancing rnas for combination with chimeric antigen receptor therapy
|
EP3752203A1
(en)
|
2018-02-13 |
2020-12-23 |
Novartis AG |
Chimeric antigen receptor therapy in combination with il-15r and il15
|
US20200061113A1
(en)
|
2018-04-12 |
2020-02-27 |
Novartis Ag |
Chimeric antigen receptor therapy characterization assays and uses thereof
|
WO2019210153A1
(en)
|
2018-04-27 |
2019-10-31 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
US20210396739A1
(en)
|
2018-05-01 |
2021-12-23 |
Novartis Ag |
Biomarkers for evaluating car-t cells to predict clinical outcome
|
US20200085869A1
(en)
|
2018-05-16 |
2020-03-19 |
Novartis Ag |
Therapeutic regimens for chimeric antigen receptor therapies
|
EP3801769A1
(en)
|
2018-05-25 |
2021-04-14 |
Novartis AG |
Combination therapy with chimeric antigen receptor (car) therapies
|
CN112203725A
(zh)
|
2018-06-13 |
2021-01-08 |
诺华股份有限公司 |
Bcma嵌合抗原受体及其用途
|
EP3844265A2
(en)
|
2018-08-31 |
2021-07-07 |
Novartis AG |
Methods of making chimeric antigen receptor-expressing cells
|
US20220364055A1
(en)
|
2018-08-31 |
2022-11-17 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
WO2020069405A1
(en)
|
2018-09-28 |
2020-04-02 |
Novartis Ag |
Cd22 chimeric antigen receptor (car) therapies
|
WO2020069409A1
(en)
|
2018-09-28 |
2020-04-02 |
Novartis Ag |
Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
|
BR112021016609A2
(pt)
|
2019-02-25 |
2021-11-03 |
Novartis Ag |
Composições de partículas de sílica mesoporosa para entrega viral
|
WO2020191316A1
(en)
|
2019-03-21 |
2020-09-24 |
Novartis Ag |
Car-t cell therapies with enhanced efficacy
|
WO2020210678A1
(en)
|
2019-04-12 |
2020-10-15 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
WO2020219742A1
(en)
|
2019-04-24 |
2020-10-29 |
Novartis Ag |
Compositions and methods for selective protein degradation
|
EP4065158A2
(en)
|
2019-11-26 |
2022-10-05 |
Novartis AG |
Chimeric antigen receptors binding bcma and cd19 and uses thereof
|
JP2023503161A
(ja)
|
2019-11-26 |
2023-01-26 |
ノバルティス アーゲー |
Cd19及びcd22キメラ抗原受容体及びその使用
|
EP4104187A1
(en)
|
2020-02-14 |
2022-12-21 |
Novartis AG |
Method of predicting response to chimeric antigen receptor therapy
|
WO2021173995A2
(en)
|
2020-02-27 |
2021-09-02 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|